PET-16 

PET-16 is a selective HSP70 inhibitor that binds to an allosteric pocket of the substrate-binding domain. PET-16 inhibits the ability of HSP70 to cycle between ATP-bound and ADP-bound states. PET-16 induces apoptosis in multiple myeloma^[1].

PET-16 (0.01-100 μM; 72 h) shows cytotoxicity in Multiple myeloma (MM) cell lines with the highest steady-state level of HSP70 showed the lowest IC₅₀^[1].
PET-16 (3 μM; 24 h) induces apoptosis in multiple myeloma, along with proteotoxic stress^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PET-16 (5-10 mg/kg; i.p.; twice a week; for 3 weeks) markedly decreases p-FAK and BRAF staining in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

443.31

C₂₆H₂₀BrP

34387-64-9

C1(C#C[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=CC=CC=C1.[Br-]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Charvann K Bailey, et al. Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma. Cancer Biol Ther. 2015;16(9):1422-6.  [Content Brief]

  [2]. Anna Budina-Kolomets, et al. HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res. 2016 May 1;76(9):2720-30.  [Content Brief]